Chronic myeloid leukemia (CML) cannot be completely eradicated from the body in most cases, but it can be controlled so effectively that many patients live normal lifespans and some stop treatment entirely. The 10-year overall survival rate for CML patients on modern therapy is 82 to 87%, and the 10-year survival rate compared to the general population of the same age is 90 to 95%. For a disease that was fatal within a few years before 2000, this represents one of the most dramatic turnarounds in cancer medicine.
The honest answer to “can CML be cured?” depends on what you mean by cured. If you mean every last leukemia cell destroyed, that remains elusive for most patients. If you mean living a full life, potentially medication-free, with no signs of active disease, that is now a realistic goal.
Why a Complete Cure Is Difficult
CML is driven by a specific genetic mutation that creates an abnormal protein fueling the growth of leukemia cells. The targeted drugs used to treat CML, called tyrosine kinase inhibitors (TKIs), are extraordinarily effective at shutting down that protein and killing active leukemia cells. The problem is that a small population of dormant leukemia stem cells essentially hibernates in the bone marrow. Because these sleeping cells aren’t actively dividing, TKIs can’t reach them.
Even patients who have been in deep remission for years, with no detectable leukemia on standard blood tests, still carry these dormant cells. This is why doctors distinguish between a “biological cure,” meaning total eradication of all leukemia cells, and a “functional cure,” meaning the disease is controlled to the point where it causes no harm and may not require ongoing treatment. A functional cure is what most CML patients can now aim for.
How TKI Therapy Transformed CML
Before 2000, the 10-year survival rate for CML was less than 10%. The approval of the first TKI, imatinib, in 2001 changed everything. With imatinib alone, about 90% of patients achieve a major molecular response over 10 years, and roughly 80% reach a deep molecular response, where leukemia is reduced to extremely low levels.
Five TKIs are now approved for first-line treatment of CML. Newer-generation drugs tend to produce deeper responses faster. In pooled analyses, second- and third-generation TKIs were about 64% more likely to achieve a deep response (called MR4) and more than twice as likely to reach an even deeper response (MR4.5) compared to standard-dose imatinib. Your doctor will choose among these based on your risk profile, other health conditions, and potential side effects.
For most patients, taking a daily pill controls CML indefinitely. The treatment is not chemotherapy in the traditional sense. It targets the specific protein driving the leukemia rather than broadly killing dividing cells, which means side effects are generally more manageable, though they vary by drug and can include fatigue, muscle cramps, fluid retention, or digestive issues.
Stopping Treatment: Treatment-Free Remission
The most exciting development in CML care is that some patients can safely stop their medication and remain in remission, a state called treatment-free remission (TFR). This is the closest thing to a functional cure currently available.
Not everyone qualifies. Current guidelines require that you have been on TKI therapy for at least 3 years, maintained a deep molecular response (a 10,000-fold reduction in leukemia levels) for at least 2 years, and never progressed beyond the chronic phase of the disease. If you meet these criteria, your doctor may discuss a carefully monitored discontinuation attempt.
The success rate is encouraging but not guaranteed. In clinical studies, roughly 55 to 60% of eligible patients who stop therapy remain in remission at 2 years. The highest-risk period is the first 6 months, when about 35% of relapses occur. After that, the risk drops sharply: only about 8% relapse between 6 and 12 months, and just 3% in each 6-month window after that.
What Monitoring Looks Like After Stopping
If you attempt treatment-free remission, you won’t simply stop your medication and walk away. The monitoring schedule is intensive, especially early on. Guidelines recommend blood tests every 4 weeks for the first 6 to 12 months, then every 6 to 8 weeks through 18 months, and every 3 months after that. These tests measure the level of the leukemia-associated gene in your blood with extreme sensitivity, capable of detecting one leukemia cell among hundreds of thousands of normal cells.
If your leukemia levels start rising above a specific threshold, you restart your TKI immediately. This is not a crisis. It simply means treatment-free remission wasn’t sustainable for you, and you go back to the approach that was already working.
What Happens If You Relapse
One of the most reassuring findings in CML research is that restarting therapy after a failed discontinuation attempt works extremely well. In the ENESTfreedom trial, 98.9% of patients who restarted treatment regained a major molecular response, and 92.3% returned to a deep molecular response. In the DESTINY trial, 91% of patients who relapsed returned to a major response within 5 months of restarting their medication. Data from the EURO-SKI trial showed that 85 to 96% of patients regained deep responses within 12 months of restarting, depending on how quickly they had relapsed.
In practical terms, attempting treatment-free remission carries very little long-term risk. If it works, you’re free of daily medication. If it doesn’t, you go back to treatment that is overwhelmingly likely to bring your disease back under control.
Stem Cell Transplant: The Only Potential Biological Cure
Bone marrow transplant (allogeneic stem cell transplant) is the only treatment that has historically been considered capable of truly eradicating CML. It replaces your bone marrow, including the dormant leukemia stem cells, with a donor’s healthy marrow. For a long time, it was the only option that offered long-term disease freedom without ongoing medication.
However, transplant carries serious risks, including graft-versus-host disease (where the donor’s immune cells attack your body), infection, and relapse. For patients transplanted in the more advanced blast phase of CML, 2-year overall survival is around 48%, and relapse rates remain high. Even among those transplanted more recently with modern supportive care, 3-year survival is about 65%.
Because TKIs are so effective and so much safer, transplant is now reserved for patients whose CML doesn’t respond to multiple TKIs, who carry specific resistant mutations, or who progress to the accelerated or blast phase. For the vast majority of patients diagnosed in chronic phase, TKI therapy offers better outcomes with far less risk.
Living With CML Long Term
The practical reality for most people diagnosed with chronic-phase CML today is a near-normal lifespan. Some will take a daily pill indefinitely. Others will eventually qualify for a discontinuation attempt, and more than half of those will succeed. The disease shifts from an acute crisis to something closer to a chronic condition, managed with regular monitoring and, for many, an eventual shot at life without medication.
The word “cure” may not technically apply to most CML patients in the strictest biological sense. But for a growing number of people, the outcome is indistinguishable from one: no symptoms, no treatment, no detectable disease, and a normal life expectancy.